Background: Xerostomia, or dry mouth, is a prevalent condition among older adults and has significant implications for oral and systemic health. It is associated with impaired chewing, swallowing, and speech, and increases the risk of oral infections, dental caries, and gum disease. Xerostomia may also contribute to malnutrition and aspiration pneumonia.
Objective: This study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia.
Methods: A single-center, randomized, double-blind, placebo-controlled trial will be conducted at Hospital Universiti Sains Malaysia from August 2025 to July 2026. Eligible participants aged 60 and above with self-reported xerostomia will be randomly assigned to receive either Oral7® Mouth Spray or a placebo spray for four weeks. The primary outcome is the mean change in Summated Xerostomia Inventory (SXI) scores between groups from baseline to post-intervention. Secondary outcomes include changes in unstimulated salivary flow rate using the sialometry technique and OHRQoL measured by the Geriatric Oral Health Assessment Index (GOHAI) at baseline and three months post-intervention. Data will be analyzed using SPSS version 29.
Conclusion: This trial will provide evidence on the efficacy of Oral7® Mouth Spray in alleviating xerostomia symptoms and improving salivary function and oral health-related quality of life in older adults, potentially guiding future clinical management of this condition.
Aged 60 years and above
Patients with often or always having dry mouth/xerostomia by asking single-item xerostomia question: "How often does your mouth feel dry?" (Adakah mulut anda sering merasakan kekeringan?). The response options were "Never (Tidak Pernah)," "Sometimes (Kadang-kadang)," "Often (Kerap)," or "Always (Sentiasa/Sepanjang masa)."
Patients who are taking nutrition orally
Patients who are able to speak
• Patients on salivary substitutes for the past one week
Oral condition that required immediate attention such as mucosal or gingival bleeding, orofacial swelling, oral pain and oral ulcer.
Patients who are deaf and mute
Those with mental disabilities or documented cognitive deficits that would impair their ability to answer questions independently.
Parallel
Oral7® mouth spray contains Natural Enzymes (Lactoperoxidase, Glucose Oxidase, Lactoferrin, Lysozyme), Calcium, Xylitol, Aloe Vera, Natural peppermint.
Combination productThis study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia
1. To compare the mean change in the Summated Xerostomia Inventory (SXI) between older patients with xerostomia taking Oral7® Mouth Spray versus older patients with xerostomia taking placebo mouth spray at baseline and after an intervention duration of 4
The minimum score for SXI is 5 and the highest score is 15 . The total score of will be calculated into a single continuous scale score which represents the severity of xerostomia; higher scores represent more severe symptoms.
unstimulated whole salivary flow rate
2\. To compare unstimulated whole salivary flow rate measurements using sialometry technique between older patients with xerostomia taking Oral7® Mouth Spray versus older patients with xerostomia taking placebo mouth spray at baseline and after an intervention duration of 4 weeks.
Assessment of Oral Health Status
2\. To assess the oral health status between older patients with xerostomia taking Oral7® Mouth Spray versus older patients with xerostomia taking placebo mouth spray at baseline and after an intervention duration of 4 weeks.
Click on the lead sponsor to view all of their trials.
ZAINAB MAT YUDIN
Lead sponsor
MBD MARKETING SDN. BHD.
Sponsor institution
